ALK and non-small cell lung carcinoma: A more recent analysis of the pooled results of NP28763 and NP28761 confirmed the promising efficacy of alectinib in the CNS for ALK-positive NSCLC patients pre-treated with crizotinib, regardless of the assessment criteria used [67].